Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.7.0.1
Stockholders' Equity (Tables)
 9 Months Ended
Apr. 30, 2017
Stockholders' Equity Note [Abstract]  
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] The amounts of share-based compensation expense recognized in the periods presented are as follows:

    Three months ended
April 30,		     Nine months ended
April 30,		  
    2017     2016     2017     2016  
Stock options   $ 204     $ 143     $ 586     $ 351  
Restricted stock     5       6       15       19  
    $ 209     $ 149     $ 601     $ 370  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

    Three months ended
April 30,		     Nine months ended
 April 30,		  
    2017     2016     2017     2016  
Cost of clinical laboratory services   $ 2     $ 2     $ 5     $ 5  
Selling, general and administrative     207       147       596       365  
    $ 209     $ 149     $ 601     $ 370  
Share-based Compensation, Stock Options, Activity [Table Text Block] The following table summarizes stock option activity during the nine month period ended April 30, 2017:

    Options     Weighted
Average
Exercise
Price		   Weighted
Average
Remaining
Contractual
Term		   Aggregate
Intrinsic
Value (000s)		  
Outstanding at July 31, 2016     1,808,875     $ 3.43            
Awarded     493,996     $ 7.07            
Exercised     (45,358 )   $ 3.28       $ 338  
Cancelled or expired     (9,000 )   $ 4.74            
Outstanding at end of period     2,248,513     $ 4.23   2.7 years   $ 10,433  
Exercisable at end of period     1,484,993     $ 3.26   1.2 years   $ 8,231  
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2017 is as follows:

    Awards     Weighted
Average
Award Price		  
Outstanding at July 31, 2016     8,501     $ 4.13  
Awarded     —       —  
Vested     (2,813 )   $ (3.49 )
Forfeited     —       —  
Unvested at end of period     5,688     $ 1.96